EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
FDA Official Urged Fatal Myocarditis Warning for COVID-19 Vaccines, but Label Change Remains Unmade
Pfizer (NYSE:PFE) Stock Falls 1.1% - Here's What Happened - Zolmax
Pfizer (NYSE:PFE) Stock Price Down 1.1% - Here's Why
Pfizer India's Meenakshi Nevatia on making new therapies more accessible
What Is Pfizer (PFE) Signaling With Its Latest Oncology Trial And FDA Win?
Asset Management One Co. Ltd. Purchases 65,805 Shares of Pfizer Inc. $PFE
Pfizer Stock Earnings Estimates Lowered by Erste Group Bank - Markets Daily
Very fat chances
Anaplastic Lymphoma Kinase-positive Non-Small Cell Lung Cancer Market is Projected to Grow by 2036 Owing to the Advancement of Novel Targeted Therapies | DelveInsight | ABNewswire
Hemophilia B Market Size in the 7MM is projected to grow at a CAGR of 8.4% over the forecast period of 2026-2036 | DelveInsight | ABNewswire
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
Pfizer (PFE) Scores Phase 3 Cancer Win As FDA Broadens Another Oncology Approval
Pfizer's ELREXFIO Meets Phase 3 Endpoint; Median PFS Not Yet Reached; Stock Down
Pfizer's ELREXFIO Succeeds In Phase 3 Trial For Multiple Myeloma
Pfizer (PFE) Set to Post Quarterly Earnings on Tuesday
Pfizer Inc. $PFE Shares Newly Bought by Leo Wealth LLC
Pfizer Secures Expanded FDA Label For Talzenna-Xtandi In HRR-Mutated Metastatic Prostate Cancer
87,500 Pfizer Inc. $PFE Shares Sold by Arnhold LLC
Pfizer Inc. $PFE Shares Sold by Oppenheimer & Co. Inc. - Daily Political
Pfizer's Talzenna-Xtandi Gets Expanded FDA Approval For Earlier Prostate Cancer Treatment
Ctrl, Alt, Cure: AI codes next miracle drug
How Much Retirement Income Could $100,000 in These 3 Dividend Stocks Generate?
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
Erste Group Bank Has Negative View of Pfizer FY2026 Earnings
Pfizer Share Price Today 26 Oct 2026: Live NSE/BSE Rates, Technical Analysis and Expert Forecasts
Pfizer announces results across serotypes in Phase 2 study of 25vPnC
Bill Gates Faces Court Over Claims COVID Jabs Were 'Lethal Biological Weapons'
Appeals Court Throws Out Alex Berenson's Case Against Pfizer Executives
Pfizer (PFE) Lung Cancer Drug Shows Survival Benefit Despite Trial Failure
DZ BANK AG Reaffirms Their Buy Rating on arGEN X (0QW0)
Pfizer Sees Path Forward for Cancer Drug Despite Trial Failure
Pfizer And 2 Other AI Healthcare Stocks To Watch
4 High-Yield Dividends That Could Be Next on the Chopping Block
Pfizer (NYSE:PFE) Stock Jumps 1.8% - Here's What Happened - Stock Observer
Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial
Pfizer (NYSE:PFE) Shares Down 1.3% - Should You Sell? - Daily Political
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
What is Erste Group Bank's Estimate for BMY FY2027 Earnings? - Stock Observer
Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
Pfizer (NYSE:PFE) Shares Climb 1.8% - Still a Buy?
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
Summit County Public Health offering updated COVID-19 vaccines
Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares - 24/7 Wall St.
Pfizer Inc. (NYSE:PFE) Stock Has Average Price Target of $28.72 According to Brokerages - Zolmax
Pfizer (PFE) Backs Sec61 Drug Hunt In New Research Collaboration
Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors
Multiple myeloma in the Netherlands: 35-year trends in incidence and survival
Small Cell Lung Cancer Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and Route of Administration Trends | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca | ABNewswire
Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial
European Commission Approves KEYTRUDA® Plus Padcev® as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer | INN
Global Life Science Market Report 2026: Size, Trends and Forecast to 2030 | Secure $200.6B AI and Precision Medicine Upside with Johnson & Johnson, Roche, Pfizer, and AstraZeneca
Global and regional burden of measles and vaccine coverage among children under 5 years, 1990−2023: a Global Burden of Disease Study
Global, regional and national burden of pertussis in 1990-2023: a Global Burden of Disease study
Pfizer (NYSE:PFE) Stock Price Up 2.4% - Still a Buy?
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%
18,032 Pfizer Inc. $PFE Shares Bought by Bank Pictet & Cie Europe AG - Zolmax
Pfizer (NYSE:PFE) Sets New 12-Month High - Here's What Happened - Zolmax
Pfizer (NYSE:PFE) Sets New 1-Year High - Should You Buy?
What Pfizer Bulls Got Right
Reviewing Nexentis Technologies (NASDAQ:NXTS) and Pfizer (NYSE:PFE) - Zolmax
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors | Morningstar
5 Dividend Stocks for Investors Who Want Income Without the Market's Wild Swings
Prediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors
Pfizer's Dividend Freeze Raises a Bigger Question About Its Cash Flow
Critical Analysis: Nexentis Technologies (NASDAQ:NXTS) versus Pfizer (NYSE:PFE) - Daily Political
Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch
$50,000 in These 5 Dividend Stocks Could Pay You $2,700 a Year
Old Pfizer building to undergo repairs after columns buckle
Peripheral T-Cell Lymphoma Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight | ABNewswire
Rare prostate cancer histologies: detection, characteristics and treatment
Pfizer (PFE) Gets a Hold from Wells Fargo
Does Expanded Tukysa Approval Change The Bull Case For Pfizer (PFE)?
Pfizer or Kraft Heinz: Only One Gets My Dividend Dollars for the Next 10 Years
RBC Capital Reaffirms Their Hold Rating on Pfizer (PFE)
Health Care Down, But not by Much, Amid Defensive Bias - Health Care Roundup | Morningstar
Pfizer (NYSE:PFE) Shares Up 3% - Here's What Happened - Zolmax
Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Tukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE)
Training the next generation of hepatologists for the cardiovascular-kidney-metabolic era
Ankylosing Spondylitis Market in the US to Grow from USD 3,366.93 Million at a CAGR of 8.36% Through 2032 | ABNewswire
Pharmaceutical Stocks To Keep An Eye On - October 15th - Zolmax
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Big pharma is pouring billions into a new class of 'protein degrader' drugs | World News
Pfizer (NYSE:PFE) vs. Iterum Therapeutics (NASDAQ:ITRM) Head-To-Head Contrast - Markets Daily
Pfizer Inc. (PFE) - What Are Researchers Thinking About This Stock?
Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies
PFIZER news
Trump Announces 25% Tariffs on Automobiles, Pharmaceuticals, and Semiconductors
Week Ahead: US And Canada Labour Markets Are In Focus, BoE Rate Decision
Latest news
Show more
Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty
September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations
Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge
